We are a pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively creating a revolutionary treatment paradigm for viral diseases, such as rabies, COVID-19, and influenza. Rabies is one of the deadliest diseases in the world, with a nearly 100% fatality rate once the virus reaches the brain (rabies encephalitis) and, unfortunately, there are currently no effective treatment interventions for rabies encephalitis. Our late-stage rabies program, headlined by our lead compound IMT504, has received Orphan Drug Designation (ODD) in the US for a rabies encephalitis treatment and we are preparing for pivotal clinical trials. A successful trial could lead to rapid FDA approval and qualification for the valuable Priority Review Voucher (PRV) and near-term revenue generation. PRVs can be sold to other institutions, with PRV sales averaging over $100M of non-dilutive cash.
Moreover, rabies represents a medically important segment of the infectious disease market that, to date, has not been adequately served. Rabies is the most lethal organism on earth, with a fatality rate of essentially 100%. In addition, rabies consistently impacts more lives annually than other viruses that are in the news, like Ebola. For example, in the 40-year history of known Ebola infections ~15,000 people have died, but in that same 40-year period, over 3 million people have died from rabies. There are currently no effective treatments for the approximately 60,000 people each year who develop an active rabies infection in the brain, all of whom will die with rare exceptions. Consequently, an effective treatment would open up a whole new market and provide much needed medical support for those afflicted by this life-threatening disease.